Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Recruiting in Palo Alto (17 mi)
+35 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Bausch & Lomb Incorporated
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Research Team
DD
Daniel Donatello
Principal Investigator
Bausch & Lomb Incorporated
Eligibility Criteria
Inclusion Criteria
I was 18 or older when I agreed to participate.
I have signed a consent form.
I have had dry eye disease in both eyes for at least 6 months.
See 7 more
Treatment Details
Interventions
- NOV03 (Other)
- Saline Solution (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NOV03Experimental Treatment1 Intervention
100% perfluorohexyloctane 4 times daily (QID)
Group II: Saline solutionPlacebo Group1 Intervention
0.6% sodium chloride solution 4 times daily (QID)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Bausch site 236Westminster, CA
Bausch site 225Grand Junction, CO
Bausch Site 204Morrow, GA
Bausch site 218Hoffman Estates, IL
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Bausch & Lomb Incorporated
Lead Sponsor
Trials
263
Patients Recruited
59,400+